Two IND submissions filed on the same day, targeting three obesity receptors with a single monthly injection, is an unusual opening move for a Hong Kong-listed biotech with no prior U.S. clinical footprint in metabolic disease. Ascletis Pharma filed with the FDA for both ASC36, a standalone amylin receptor agonist, and ASC36_35 FDC, a co-formulation pairing ASC36 with its GLP-1R/GIPR dual agonist ASC35, both designed for once-monthly subcutaneous dosing. The strategic logic is visible in the preclinical numbers: in diet-induced obese rat studies, ASC36_35 FDC produced approximately 51% greater relative body weight reduction than co-administered eloralintide and tirzepatide, a benchmark pairing that itself delivered 29% weight loss at 32 weeks in recently presented human data from Eli Lilly.
The mechanism behind that efficacy gap matters clinically. Eloralintide and tirzepatide require two separate weekly injections; ASC36_35 FDC collapses both into one monthly shot through Ascletis’s proprietary Self-Assembling Lipid Depot formulation. In non-human primate studies, ASC36 showed roughly six times the observed half-life of eloralintide, which is what enables the extended dosing interval. The amylin receptor angle is also worth attention on its own: ASC36 monotherapy outperformed petrelintide and eloralintide monotherapies by approximately 91% and 32% in head-to-head rodent studies, respectively. Those are large margins, even accounting for the well-known limits of DIO rat models as translational tools.
The broader context is that obesity pharmacology is now crowded at the GLP-1 layer but still sorting out whether amylin receptor engagement, alone or in combination, adds meaningful and durable weight loss on top of incretin mechanisms. The FDA’s expanded approval of semaglutide in March 2024 to cover cardiovascular risk reduction raised the efficacy and outcomes bar for the entire class. Ascletis is entering that competitive environment with preclinical data, AI-assisted drug discovery, and a formulation platform, but no Phase I human data yet in this indication. Its GLP-1R/GIPR asset ASC35 did receive FDA IND clearance for a Phase I trial in June 2026, which provides one anchor point of regulatory confidence.
The single number to track from the first human Phase I readout for ASC36 is the pharmacokinetic half-life in people, specifically whether the six-fold NHP advantage over eloralintide survives the translation to human subjects. If it does, the once-monthly dosing claim holds and the combination program gets a credible foundation. If the half-life compresses significantly, the entire differentiation argument around ASC36_35 FDC collapses before any efficacy data are in hand.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
